Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eaaOCfbwoceTmGtFjvqp

November 16, 2012News for the food and drug law community

  Drugs & Biologics 
  • Hamburg to Senate: "I wish that responses had been more timely"
    Regulators could have done more and worked together better before the meningitis outbreak linked the New England Compounding Center, but the agency's power to act was "limited, unclear and contested," Commissioner Dr. Margaret Hamburg testified Thursday before a Senate panel. An owner of the NECC who cited his Fifth Amendment rights and did not testify at Wednesday's House hearing on the outbreak did not appear at Thursday's Senate hearing. Politico (Washington, D.C.) (11/16) Email this Story
  • Senators open to changes in regulation of compounders
    Republican and Democratic senators indicated at a hearing Thursday that they would be open to changes in the oversight of compounding pharmacies to prevent outbreaks like the one tied to tainted steroid injections from the New England Compounding Center. Sen. Lamar Alexander, R-Tenn., said the FDA could be given the power to certify states to regulate large-scale compounders, and the FDA would have the ability to decertify states that don't live up to the responsibility. Reuters (11/15) Email this Story
  • FDA panel: Data on effects of Dynavax's hep B vaccine insufficient
    The FDA's Vaccines and Related Biologics Advisory Committee voted 13-1 in support of the efficacy of Dynavax's hepatitis B vaccine Heplisav, but they questioned its safety and asked whether more trial data was needed involving blacks, Asians and Hispanics. The FDA could decide on the application by Feb. 24. MedPage Today (free registration) (11/15) Email this Story
  • Deal with states over Avandia promotion to cost GSK $90M
    GlaxoSmithKline will pay 37 U.S. states and Washington, D.C., $90 million to settle allegations that it illegally promoted diabetes treatment Avandia. The deal resolves claims that GSK misled consumers about the risk of strokes and heart attacks tied to the drug in order to improve sales. "This settlement ... marks an important step in resolving long-standing legal matters," company spokeswoman Bernadette King said. Bloomberg Businessweek (11/15) Email this Story
The Key To Positive Cash Flow
Every business is cyclical with cash flow ups and downs. The key is to find a way to keep the cash coming in as predictably as possible. Seem impossible? Well it's not. There are systems and processes that make it easier to collect the cash you've earned so your small business can grow. Learn how these small-business owners set up their businesses for success.

  Global Focus 
 
SHRM Exec Study: Impact of Absence
Read the compelling results of this 2014 survey conducted by SHRM and Kronos® that demonstrate how a clearly defined strategy to monitor and manage absence, with proper training and automation, can help control costs associated with absences and improve your bottom line. Click here to learn more.

  Food & Dietary Supplements 
 
  • Health group seeks FDA action on caffeinated snack
    The Center for Science in the Public Interest is urging the FDA to act against Cracker Jack'D, a new Cracker Jack product with caffeine, arguing that it is not healthy for children. "The FDA considers caffeine safe for use in cola-type beverages up to 0.02 percent," CSPI wrote. "The lack of a standard for other products makes its use in those illegal." The Hill/Healthwatch blog (11/14) Email this Story
Combating Identity Theft in a Mobile, Social World
Mobile connectivity threats extend from consumers to the business environment. But who is really responsible for securing sensitive information? Smart business leaders are becoming proactive on the matter. Learn how to get protected in this white paper. Download the white paper now.

  Medical Devices 
 
  • Cook gets FDA OK for device to treat peripheral artery disease
    The FDA has granted Cook Medical approval for its Zilver PTX drug-eluting peripheral stent, the first such device to be approved in the U.S. The self-expanding metal stent, which is coated with the paclitaxel drug, is used to reopen blocked or narrowed femoropopliteal arteries in patients with peripheral artery disease. MedCityNews.com (11/15) Email this Story
  • Teleflex's vascular access catheter scores 510(k) clearance
    The FDA has cleared Teleflex to market its Nylus catheter, which is delivered peripherally to the central venous system. The device was first cleared in Europe in July and is intended to help minimize the risk of blood clot-related complications during infusions, among other applications. BeckersASC.com (11/15) Email this Story
  • Medtech leaders hit Capitol Hill to push for end to device tax
    A group of 50 top industry executives descended on Capitol Hill this week to inform lawmakers about the 2.3% medical device tax's "devastating effect" on jobs and get them to repeal it during the lame-duck session, said David Nexon of the Advanced Medical Technology Association. "[T]his excise tax will raise our industry's federal tax liability by an amount equal to a whopping 29% of our current income tax payments," Nexon said, referencing an AdvaMed report released Wednesday about the cost of the device tax. MedCityNews.com (11/14) Email this Story
Whitepaper: SDN: How do you get there from here?
Are the growing data needs of mobile, cloud, big data and social threatening today's enterprise networks? Scalable processes, a phased integration approach and the appetite to optimize over time are key components of a modern network. It's how agile organizations prepare for the data needs of tomorrow.
Explore the whitepaper to start down the path toward SDN.

  Tobacco 
  FDLI Items 
  • Is Calif.'s Proposition 65 as Applied to Dietary Supplements in Conflict With Federal Law?
    This issue of Policy Forum (Volume 2, Number 21), Is California's Proposition 65 as Applied to Dietary Supplements in Conflict with Federal Law?, explores whether private litigation actions under California's "Safe Water and Toxic Enforcement Act of 1986" (Proposition 65) should be preempted when state requirements conflict with FDA. Authors Nicolas Licato, general counsel for Nexgen Pharma, and Michael Lanosa, law student at the University of Southern California, describe a savings clause that allows California-specific requirements in Proposition 65 to prevail, even when they conflict with federal requirements. Licato and Lanosa conclude that FDA should adopt national standards for contamination of dietary supplements, and that any settlement agreements which hold manufacturers to a state-specific standard should be preempted by federal law. Members: Download now. | Nonmembers: Purchase for $24.95. Email this Story
Learn more about FDLI ->About FDLI  |  Join FDLI  |  Conferences  |  Publications

 
Position TitleCompany NameLocation
Attorney ISMC/MHS Contracts Team ManagerMcKesson CorporationSan Francisco, CA
Senior Corporate CounselMedivationSan Francisco, CA
PCH Planning & Reporting MgrPfizer inc.Manila, Philippines
Regulatory CounselBecton DickinsonFranklin Lakes, NJ
Regulatory Counsel, GlobalConfidentialNorthern, NJ
Senior Counsel - Regulatory and Quality Assurance ComplianceThe Procter & Gamble CompanyCincinnati, OH
Sr. Brand AttorneyNovo NordiskPrinceton, NJ
Health & FDA Business AssociateGreenberg TraurigWashington, DC
Click here to view more job listings.

  SmartQuote 
Wisdom is not acquired save as the result of investigation."
--Sara Teasdale,
American poet


Email this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
Job Board:  Jackie Basso (202) 407-7871
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent FDLI SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information